Westminster Health Forum

This conference discussed next steps for elective care recovery and addressing waiting times for healthcare in England.

It was a timely opportunity to discuss implications for policy and practice of recommendations for the Government in Lord Darzi’s recent Independent Investigation of the National Health Service in England, including around continuing the shift in care closer to home, increased use of technology including AI, and improving management structures and systems to better support frontline services.

Sessions also examined the way forward for government proposals for increasing weekly appointments by 40,000, pooling local resources, and utilising independent sector capacity. It also comes as the Government plans to launch a Fit for the Future Fund, which would aim to double the number of CT and MRI scanners in the NHS over the next five years.

Stakeholders and policymakers assessed practicalities of delivering increased appointments, including considerations for engagement with the workforce and implications of changes to working hours and practices, against the backdrop of industrial action and concerns including increased pressure on staff. Delegates also considered enabling strategies such as the development of reliable booking systems and infrastructure for the NHS estate to support increased appointments, as well as the Health Secretary’s recent announcement that high intensity theatre list models will be rolled out to 20 hospitals in England.

Agenda sessions considered the role of the independent sector going forward in supporting elective recovery. Areas for discussion included overcoming barriers in local commissioning arrangements and challenges around public-private collaboration, awareness of a patient’s right to choose, ensuring independent sector capacity is being used effectively for conditions which help relieve NHS pressures, and addressing concerns around privatisation and variation in patient access.

Delegates discussed practical considerations for pooling resources and creating shared regional waiting lists, looking at priorities for collaboration and the role of integrated care systems, utilising data and technology to manage waiting lists, and making sure changes are not a disincentive for organisations that have been performing well.

We also expected delegates to consider priorities for modernisation through the planned Fit for the Future Fund, including developing the requirements for infrastructure, technology and the workforce to deliver updated scanners and utilise AI, as well as opportunities for delivering improved diagnostics and detection of conditions closer to communities.

Further sessions assessed priorities for managing and supporting patients awaiting diagnosis and treatment, including approaches such as taught self-management and care. Delegates discussed challenges within primary care, looking at discharging patients into social care and options for advancing integrated care across the full patient pathway before, during and after treatment through the National Perioperative Care Programme.

We are pleased to have been able to include keynote sessions with: Dr Katharine Halliday, President, Royal College of Radiologists; David Hare, Chief Executive, Independent Healthcare Providers Network; Dr Jo Andrews, Chief Medical Officer, Carnall Farrar; Professor Kariem El-Boghdadly, Clinical Lead, Research Lead, and HIT Lists Co-Lead, Guy’s and St Thomas’ NHS Foundation Trust; and Dr Ellen Welch, GP; Vice-Chair, Doctors’ Association UK; and Vice-Chair, North Cumbria Local Medical Committee.

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices. This includes the full proceedings and additional articles submitted by delegates. Those that attended include officials from DBT; DHSC; Home Office; OLS; DoH, NI; and the Welsh Government.

This conference examined the future of AI in healthcare - looking at key issues for development, adoption and regulation.

It took place with the Secretary of State for Health and Social Care outlining the new Government’s plans to harness the power of AI technologies, with £1.5bn announced by the Chancellor in the October Budget that will in part go to doubling the number of AI-enabled diagnostic scanners. In light of the Chancellor outlining a further £2bn to invest in NHS technology and digital, this conference discussed priorities for AI within this area of investment, as well as options to support growth, with the Artificial Intelligence Opportunities Action Plan expected shortly.

The conference was also an opportunity to assess how the Government’s recently launched Regulatory Innovation Office can best approach setting and monitoring targets for regulatory approval. Areas for discussion included managing responsibility and safety alongside a drive for innovation, international competitiveness and leadership in best practice, and providing clarity and increased certainty for industry.

The conference brought together stakeholders, regulators and policymakers to assess the way forward for widening use of AI to support key areas in healthcare, including issues around safety and ensuring the readiness of healthcare systems and infrastructure for effective integration and rollout as the Government launches a consultation on a new 10 Year Health Plan for the NHS.

Delegates discussed the future for regulation and legislation affecting AI-based technologies, next steps for research and development, and supporting healthcare staff in adoption and adapting to the use of AI technologies.

With the MHRA outlining priorities in its Impact of AI on the regulation of medical products report, we expected discussion on options for a regulatory framework that meets the agency’s aim of a proportionate approach that takes into account unique challenges in this area, and how innovation can best be supported. It came alongside the launch of a new regulatory sandbox for AI as a medical device (AIaMD) to identify challenges for safe development and deployment.

Areas for discussion included options for managing risk while maximising benefits, the evidence and methods of evaluation that will be required to ensure patient safety and robust regulatory processes, support for industry in navigating the regulatory landscape, and improving access to quality datasets and developing data-related regulation.

We also expected discussion on funding priorities for AI development in healthcare, looking at cost-benefits, stimulating investment and the balance between private and public funding. Frameworks for collaboration between the NHS, developers, government and regulators werr discussed, as well as issues relating to oversight and governance, intellectual property, responsibilities and liability, and evaluating impact.

Further sessions looked at how equality in access to AI developments across the country can be achieved and next steps for addressing variation. They assessed priorities for training NHS staff in the context of workforce shortages, updating digital infrastructure to support implementation, and developing a strategic route for scaling up the use of AI in small pilot projects for rollout across the NHS.

We are pleased to have been able to include keynote sessions with: Russell Pearson, AI Regulatory Policy and Projects Lead, MHRA; Gemma Warren, Policy Manager, AI and Data, HRA; Dr Rishi Das-Gupta, Chief Executive, Health Innovation Network, South London; Dr Andrew Leary, AI Manager, Royal College of Radiologists; and Professor Mihaela van der Schaar, John Humphrey Plummer Professor, University of Cambridge; and Director, Cambridge Centre for AI in Medicine.

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices, and more widely. This includes the full proceedings and additional articles submitted by delegates. As well as key stakeholders, those that attended include parliamentary pass-holders from the House of Commons and officials from DHSC; DSIT; DBT; ONS; ICO; CQC; OLS; MHRA; HSE; PHA; UKHSA; Dstl; GO-Science; DfE; DfT; HMPPS; the Welsh Government; and The Scottish Government.

This conference discussed next steps for digital health and the adoption of medical technology in England.

Bringing together stakeholders and policymakers, it was an opportunity to discuss priorities for the new Government around funding, regulation and improving patient access to digital health and medical technology.

It comes with the Secretary of State for Health and Social Care pledging to make Britain a powerhouse for medical technology and life sciences, and calling for a more effective culture of innovation.

With proposals put forward by NICE and NHS in May 2024 to accelerate the adoption of safe and cost-effective healthcare products, it was also an opportunity for stakeholders and policymakers to examine what is needed to further align medical technology developments with clinical needs, and to assess opportunities for regulation to improve patient access to innovation.

It also took place with further plans from MHRA for devices certified by approved international regulators to be used in the UK, as well as streamlining regulatory processes and minimising duplicate certification to accelerate patient access, with concerns from industry over how certification will work in practice.

Delegates considered funding priorities for digital innovation and medical devices to modernise the NHS, looking at next steps for the Fit for the Future Fund, and developing earlier diagnosis through adoption of innovative technologies in line with the new Government’s shift towards preventative models of care.

Stakeholders and policymakers also discussed the role of the workforce moving forward, and priorities for delivering the NHS Long Term Workforce Plan for training to accelerate the implementation of devices and digital technologies across healthcare delivery.

Delegates assessed next steps for improving collaboration between regulators and industry, with the Innovative Devices Access Pathway (IDAP) launched last year, which aims to develop a framework to improve regulation, assessment and access pathways, alongside proposals in the MHRA Regulatory Roadmap published earlier this year. Areas for discussion included the progress of the pilot, how regulation can keep pace with innovation going forward, and the potential for introducing training programmes to boost understanding of new developments.

It was also an opportunity to discuss the new Government’s approach to maintaining safety alongside innovation following the independent review Equity in medical devices, which highlighted bias affecting certain groups in areas such as research, AI algorithms and functioning of medical devices. Approaches to safely accelerating the deployment of AI into NHS care were discussed, as the Government plans to double the number of AI-enabled CT and MRI scanners in the NHS, and the way forward for personalisation of new tech, such as wearables for managing conditions and improving healthcare outcomes.

Further sessions assessed progress and next steps for tackling barriers to adoption of technology in health systems, including priorities for resourcing the NHS to adopt innovation, expanding the use of the NHS app across health services, utilising the federated data platform and sharing patient records in order to improve efficiency, and the use of virtual wards to reduce waiting times and increase bed capacity.

Overall, areas for discussion included:

• digital technologies in healthcare delivery: assessing progress in adopting and embedding digital transformation - key priorities moving forward - infrastructure needs
• regulation pathways: streamlining regulatory pathways to accelerate uptake of innovative technologies - assessing the innovative devices access pathway framework - priorities for patient safety
• tackling bias in medical devices: guidance for regulators, clinicians and developers - patient access to medical devices and digital technologies - patient-centred approaches to digital inclusion 
• research and innovation: addressing barriers to funding for developers - options for incentives - supporting innovation to help meet unmet medical needs 
• collaboration: opportunities for coordination to accelerate adoption - expanding use of the NHS app - increasing record-sharing between services - leadership within ICSs moving forward
• virtual wards: options for expanding utilisation - the role of new medical technologies in supporting NHS bed capacity
• workforce: priorities for education and improving digital literacy within the NHS - workforce ambitions for digital transformation outlined in the plan for digital health and social care
• tackling barriers to adoption: interoperability - improving systems between primary and secondary care - supporting the adoption of the FDP - harnessing data and addressing variation between services - digital systems procurement

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices. This includes the full proceedings and additional articles submitted by delegates. Those that attended include officials from DHSC; DSIT; HSE; MHRA; OLS; UKHSA; DBT; Department for the Economy, NI; and The Scottish Government.

This conference focused on priorities and the pathway for long-term workforce planning, training, retention and reform in England.

Delegates discussed next steps for the delivery of the NHS Long Term Workforce Plan, which looks to address the projected workforce shortfall over the next 15 years, including doubling medical school places to 15,000 by 2031/32.

The conference was an opportunity for stakeholders and policymakers to discuss priorities for the new Government following findings in Lord Darzi's recent Independent Investigation of the National Health Service in England. Delegates examined key issues affecting the workforce that the report draws out, including the need for new approaches to improving recruitment and retention, and supporting staff welfare and mental health, along with professional development and training to keep staff up to pace with advances in technology.

Attendees assessed what will be needed to create the increased medical education and nursing training places as set out in the Plan, along with implications and opportunities for stakeholders in the health, social care, education and training systems.

Areas for discussion included priorities for building the academic workforce to meet targets for increased places and options for revising the length of programmes so newly qualified professionals can enter the workforce more quickly.

Increasing accessibility and options for apprenticeships for key roles were discussed, as well as building capacity for this type of training. Discussion also considered strategies for reducing reliance on international workers and improving resilience within the domestic workforce, including whether funding and plans go far enough to achieve this within current timeframes.

The discussion took place in the context of the extended period of industrial action within the NHS, and initiatives from the Secretary of State aimed at their resolution.

Putting resources in place for managing and paying staff, including those coming in through new training places were also discussed, as well as key considerations for where newly qualified staff are posted in relation to patient need, including addressing GP shortages.

It was an opportunity to consider options for improving NHS workforce planning, following NAO’s report published in March which set out recommendations to make the model more accurate for future decision-making.

We also expected delegates to look at improving retention within the workforce, including latest thinking on improving career pathways and contributing to research, plans to retain older workforce members in the NHS and whether reforms to the pension scheme and flexible working options are enough. They also considered the role of integrated care systems in delivering planning and culture change locally for the workforce, and developing best practice for retaining the workforce in disadvantaged areas.

Further sessions looked at the way forward for reform, including the role of regulation in new advanced and associate professional roles, and the outlook for developing internship models and how this could work in practice. Priorities for ensuring the workforce has the right skillsets for operating innovative digital health methods and working with multi-morbidity patients were also discussed, as well as next steps for effective leadership following government proposals to form a new Royal College of Clinical Leadership.

We are pleased to have been able to include keynote sessions with: Dr Alan Clamp, CEO, Professional Standards Authority for Health and Social Care; James Freed, Deputy Director, NHS Digital Academy; Tim Phillips, Director, Health Value for Money, NAO; Martha Roberts, Chief People Officer, Bedfordshire, Luton and Milton Keynes ICS; and Hiba Sameen, Lead Economist, REAL Centre Team, The Health Foundation.

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices. This includes the full proceedings and additional articles submitted by delegates. Those that attended include officials from DHSC; DWP; HSE; MHRA; The Scottish Government; and the Welsh Government.

This conference discussed the future for prevention and improving outcomes for major health conditions in England.

Following the publication of Lord Darzi's Independent Investigation of the National Health Service in England, commissioned by the new Government, it was an opportunity for stakeholders and policymakers to discuss the report’s implications, the strategic direction for prevention and improving patient health outcomes for major conditions, and policy priorities for the Government as they develop a 10-year plan for the NHS and their mission for health.

Delegates examined key issues that the report draws out, including the rising prevalence of long-term conditions, increased mortality rate of those living in deprived areas, cancer care which lags behind other countries, and an overall shortfall of capital investment.

Areas for discussion included what findings in the report will mean for major conditions research, diagnosis and care of the commitment to transition the NHS to a more preventative model, with aims to improve life expectancy and alleviate the financial impact of long-term sickness.

Looking at the new direction emphasising prevention, attendees discussed implementation of innovative approaches to earlier and more personalised diagnosis, including the Government’s aim to utilise the Fit for the Future Fund to double the number of MRI and CT scanners, alongside challenges for the workforce, and the way forward for patient-centred strategies.

The agenda also included a focus on the shift towards a multi-morbidity approach, looking at opportunities and challenges of a potential transition in health service planning from a single-disease approach, and listening to patient voices to inform future direction.

Further sessions considered priorities for managing health conditions and approaches to personalised care. Areas for discussion included next steps for earlier detection and diagnosis of major health conditions, and building on current NHS Screening programmes and Early Intervention Psychosis services to undertake more personalised and targeted screening. The potential of AI to improve efficiency and reduce diagnostic wait times was also discussed, looking at collaboration with developers to test AI diagnostic tools.

There was also discussion on the current NHS workforce model, looking at priorities for pivoting to a whole-person care model, the future for general and specialist professions within care teams, next steps for recruitment and retention, and more closely aligning mental and physical health services.

We also expected discussion on priorities for public health strategies, as well as the way forward for integrated care boards to adopt and adapt approaches that best suit the needs of their populations. It was also an opportunity to assess key priorities for tackling health inequality, including enhancing the collection and utilisation of data to improve understanding of this issue, with calls to establish a central consensus on ethnicity coding within the health and social care setting.

Sessions assessed what is needed to support cross-government collaboration to tackle wider socio-economic determinants to ill health and opportunities for the new parliament, as well as the funding and provision of local community health services.

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices. This includes the full proceedings and additional articles submitted by delegates. Those that attended include officials from DHSC; DSIT; MHRA; OLS; POST; HM Treasury; DfE; HMPPS; and The Scottish Government.

This conference focused on the way forward for decarbonisation and moving towards net zero in the UK life sciences sector.

It was also an opportunity for stakeholders and policymakers to discuss priorities for the new Government, including supporting growth in the sector alongside efforts and requirements to meet net zero targets, with the Secretary of State for Health and Social Care pledging to make Britain a powerhouse for medical technology and life sciences.

Delegates discussed opportunities and challenges for implementation of the NHS net zero supplier roadmap and stakeholder carbon reduction plans, looking at net zero benchmarks for procuring goods, services and works for the NHS.

There was a focus on:

• reaching supplier benchmarks, with discussion on UK Scope 1 and 2 emissions following the extension to Carbon Reduction Plan requirements to cover all new procurement from April 2024
• practical strategies for tackling Scope 3 emissions and overcoming challenges in measurement and monitoring

With a policy focus on speeding up the shift to net zero procurement, sessions in the agenda examined next steps for collaboration between key stakeholders and what is needed to secure achievable and cost-effective solutions. Areas for discussion included improving the role of data and AI in measuring and monitoring emissions in the supply chain, opportunities for sustainable sourcing, operational changes in the life sciences sector, priorities for innovative product development, and the potential role of regulation moving forward.

Sessions in the agenda brought out latest thinking on how to address challenges and issues in areas such as increasing reusability, and refitting fleets and buildings. Delegates discussed issues for funding, procurement and the supply chain, including the impact of international developments in regulation.

Further sessions explored progress so far on net zero benchmarks, looking at best practice cases and carrying forward successes, such as upstream transportation and distribution, eliminating toxic and plastic waste, and sustainability within laboratories, as well as efficiently transitioning to renewable power and alignment on common supplier standards.

Delegates also discussed frameworks for deepening collaboration on decarbonising care pathways, including pharma’s role in strengthening coordination between smaller companies to progress net zero initiatives across the healthcare work stream. There was discussion on implementing a proposed end-to-end care pathway emissions calculation standard and tool for specific diseases.

The agenda also brought out latest thinking on priorities for moving towards greener clinical trials, potential models and funding requirements, employing data-driven sustainability, and next steps for fostering innovation in clinical research. Areas for discussion included developing a taskforce, with aims to leverage digital health solutions to decarbonise clinical trials, as well as incentivising research organisations and related suppliers to measure and reduce emissions.

We also expected discussion on the NHS Clinical Waste Strategy, looking at options for improving the recyclability of products, utilising more natural materials and considering product end-of-life as part of efforts to reduce emissions, as well as the role of the NHS Greener Plan, with proposals for green heat solutions by 2025 and targets for becoming the world’s first net zero national health service.

We are pleased to have been able to include keynote sessions with: Dr Susan Simon, Chief Environmental Sustainability Officer, Medical Research Council; Dr Fiona Adshead, Chair, Sustainable Healthcare Coalition; Claire Lund, Head, Environmental Sustainability, GSK; and Emily May, Life Sciences Research Manager, Centre for Health Solutions, Deloitte.

Overall, areas for discussion included:

• net zero benchmarks: the way forward for achieving NHS goods, services and works reduction targets - priorities for implementing the Greener NHS initiative and its contribution to overall net zero goals
• Carbon Reduction Plan: next steps for reaching supplier benchmarks, following the extension of requirements from April 2024 - accelerating the transition to net zero procurement
• addressing Scope 3 emissions: building a sustainable life sciences roadmap - priorities for governance, capability building and continuous support for sustaining change
• pharma: exploring transparency and fairness in net zero plans from life science companies - the role of the taskforce and opportunities for collaboration - priorities for pharmaceutical emissions reduction targets
• innovation: leveraging innovation, data and technology to drive cost-effective reduction of emissions - adoption of digital products and services
• waste: reducing waste and developing environmentally sustainable packaging, devices and tools - waste management - latest thinking on reducing use of plastic and sustainable alternative options
• NHS: integrating environmental sustainability into NHS procurement practices - balancing cost-effectiveness with maintaining patient safety and quality of care - reducing emissions in patient pathways
• clinical research: developing best practice and models of sustainable delivery and research - opportunities for decentralised clinical trials and virtual delivery
• safety: ensuring implementation of green NHS clinical practices is safe for the workforce and patients - expanding safe reuse of laboratory tools
• coordination: opportunities for collaboration across the sector to achieve emissions reduction targets - supporting smaller companies with compliance and transition strategies

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; OLS; Defra; DBT; Department for the Economy, NI; FCDO; The Scottish Government; and the Welsh Government.

All delegates were able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices. This includes the full proceedings and additional articles submitted by delegates.

This conference discussed next steps for diagnosis, treatment and care of rare diseases in England.

Stakeholders and policymakers assessed key issues for improving health outcomes for patients with rare diseases, as well as priorities for clinical research and access to innovative treatments.

Delegates discussed strategic direction for rare disease policy in the new parliament, following the 2024 England Rare Diseases Action Plan for delivering the wider UK Rare Diseases Framework.

As well as looking at ambitions in the framework, delegates discussed the way forward for issues being raised as a focus by stakeholders and policymakers including:

• equity in access to specialised care that is close to home for patients, tackling geographical variation, and supporting patients without a diagnosis or genetic condition
• improving the delivery of clinical research and communication around genomics within the workforce

Looking at next steps for earlier detection and diagnosis of rare diseases, delegates assessed strategies for reducing waiting times for genetic testing, developing materials and training for the workforce to understand genomic processes and results, and more efficient ways of utilising data.

Those attending also discussed the newborn screening programme, including the scope of conditions that are covered, as well as practicalities for rolling out whole genome sequencing for babies as part of future iterations of the programme. They also considered how to address challenges in the transition between child and adult services following the recently updated NICE quality standard, as well as developing innovative treatments for children.

The delivery of care for rare diseases was examined, including strategies for monitoring progress in highly specialised care across the country, developing best practice in holistic care for patients, and next steps for fair access to mental healthcare across types of rare conditions.

Further sessions included discussion on progress of the Innovative Medicines Fund in patient access to innovative treatments for rare diseases and the engagement of pharmaceutical companies with the scheme so far. Delegates discussed the role of the Rare Therapies Launch Pad in piloting a pathway to support future development and regulation, as well as funding and considerations on improving models and delivery of clinical trials for rare conditions.

We are pleased to have been able to include keynote sessions with: Dr Graham Shortland, Vice-Chair, UK National Screening Committee; Ana Lisa Tavares, Clinical Lead, Rare Disease Research, Genomics England; Professor Timothy Barrett, Director, Centre for Rare Disease Studies, University of Birmingham; Dr Lucy McKay, CEO, Medics4RareDiseases; and Dr Lincoln Tsang, Partner, Ropes and Gray.

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; MHRA; OLS; UK NSC; and DBT.

The proceedings of the conference will be circulated more widely, to Parliamentarians, ministerial offices, and government and regulatory officials with an interest in the issues being discussed. All delegates will also receive a video recording of the conference.

This conference focused on next steps for pharmacy in England and priorities for the workforce.

With pharmacy services being highlighted as a focus in general election campaigning, the conference was a timely opportunity for delegates to discuss priorities for policy in the new parliament.

Delegates discussed initial delivery of the newly launched Pharmacy First scheme, which aims to give patients faster access to care and treatment for seven common conditions without needing a GP.

Sessions in the agenda looked at:

• progress with the scheme and options for expansion
• what is needed to address issues raised by stakeholders so far, including concerns over funding, staff shortages and time pressures affecting implementation
• the impact of medicine shortages and priorities for tackling medicine supply chain challenges to improve delivery of the scheme
• how joint-working between pharmacies and GP surgeries can be improved and next steps for engagement with local communities, including increasing service use and public awareness
• the impact the scheme has had on managing pressures within primary care so far

Delegates discussed the way forward for digital technologies to support the delivery of pharmacy, including improvements to digital infrastructure and compatibility across primary care, integration of patient records and electronic prescriptions, and safety and inclusion in the development of digital pharmacy.

With increasing demand for pharmacy and the range of services on offer through new schemes, the agenda brought out latest thinking on priorities for building workforce capacity, addressing workforce challenges and options for regulation to support safe care delivery with expansion of the profession. Sessions also looked at options for filling gaps in the short-term and the impact of incoming changes, including all newly qualified pharmacists being independent prescribers by 2026 and plans for increasing training places for technicians by 50%.

It was also an opportunity to assess options for future deals, as the Community Pharmacy Contractual Framework 2019-2024 comes to an end this year. Delegates will consider ways of improving and supporting service development, addressing financial challenges in pharmacy, and the future use of pharmacist skills in supporting primary care delivery.

Keynote speakers who have agreed to take part include: Alastair Buxton, Director, NHS Services, Community Pharmacy England; Nick Kaye, Chair, National Pharmacy Association; Director, Hendra’s Pharmacy; and CEO, Community Pharmacy Cornwall; and Gisela Abbam, Chair, General Pharmaceutical Council. We are re-confirming the availability of speakers in the pre-election period.

The conference was an opportunity for stakeholders to consider the issues in the presence of key policy officials who attended from DHSC; Department of Health, ROI; HM Treasury; and NAO.

The proceedings of the conference will be circulated more widely, to Parliamentarians, ministerial offices, and government and regulatory officials with an interest in the issues being discussed. All delegates will also receive a video recording of the conference. 

This conference focused on next steps for patient safety standards in healthcare delivery and priorities for improving incident response times across England.

It was an opportunity to discuss key issues at a time of heightened focus on related areas of policy in the run up to the general election.

Attendees discussed implementation of Martha’s Rule, which aims to provide patients, families, carers and staff with 24/7 access to a rapid review from a separate critical care team when concerns arise about a patient’s deteriorating condition.

Delegates examineed the preparation and enactment of Martha’s Rule in healthcare settings and its impact on the NHS workforce, including using the Learn from Patient Safety Events (LFPSE) service to reduce patients’ risk of sepsis. They considered key issues for incorporating restorative practices into incident resolution and opportunities for whole-system learning.

Sessions in the agenda explored latest developments from the NHS Patient Safety Strategy, including the Patient Safety Incident Response Framework (PSIRF), with organisations transitioning to the framework before autumn last year. Outlining new systems which shift focus towards factors that contributed to mistakes being made, it was an opportunity to learn from early adopters and consider priorities for the effective delivery of new systems and cultural change.

Further areas for discussion included implications of medical AI on patient safety, patient monitoring and innovation in personalised care. Attendees looked at protecting patients from harms associated with new technologies, and addressing health inequalities and potential biases in the design of medical devices.

Delegates also assessed latest thinking on how to address service variation through patient partnerships in order to standardise patient safety practices across NHS trusts, and next steps for improving system-wide learning post Martha’s Rule.

Overall, areas for discussion included:

• Martha’s Rule: integration into care frameworks and healthcare delivery - driving personalised care - best practice for the workforce - incorporating restorative practices into incident resolution
• opportunities for whole-system learning: removing stigma from reporting - keeping tribunals in-house - developing better incident reporting practices
• innovation: implications of AI on patient safety - opportunities for patient monitoring and personalised care - protecting patients from harms associated with new technologies - addressing health inequalities and other biases in medical devices
• workforce: enabling appropriate training - implementation and use of the Patient Safety Incident Response Framework - the role of leadership and management in supporting cultural change - addressing variation
• whole-system approach: adopting better system learning that incorporates feedback mechanisms to ensure preventative measures, rather than reactive legislation - progress so far from the LFPSE service

The conference was an opportunity for stakeholders to consider the issues in the presence of key policy officials who attended from DHSC; MHRA; DoH, ROI; The Scottish Government; and the Welsh Government.

The proceedings of the conference will be circulated more widely, to Parliamentarians, ministerial offices, and government and regulatory officials with an interest in the issues being discussed. All delegates will also receive a video recording of the conference.  

This conference discussed the future for dementia diagnosis, care and research in England.

With the Major Conditions Strategy dropped ahead of the election, and with prevention and earlier diagnosis of major conditions being highlighted as a focus in general election campaigning, the conference was a timely opportunity for delegates to discuss wider issues for dementia, as well as priorities for policy in the new parliament.

Those attending examined ambitions and options moving forward, including:

• supporting earlier diagnosis for dementia by improving understanding of inequalities and risk
• the role of integrated care systems in delivering system leadership and building relationships between primary care, memory clinics and public services
• utilising data and innovative dementia profiling tools to identify at-risk populations, and priorities for improving IT systems
• best practice for primary care in facilitating early intervention

With treatments approaching regulatory approval and NICE appraisal, it was also an opportunity to discuss next steps for patient access to treatments and their adoption in the NHS, as well as achieving the levels of earlier diagnosis required for them to be effectively delivered.

Further sessions focused on priority areas for dementia research and progress made so far on the Dame Barbara Windsor Dementia Mission, which aims to provide funding and help accelerate development of new treatments for dementia and neurodegenerative conditions though cross-sector collaboration, with the ambition of doubling dementia research by 2024/25.

Delegates assessed priorities for funding and increasing research collaboration to advance innovation in detection, delivery of clinical trials and development of precision therapy for dementia.

Overall, areas for discussion included:

• progress: long-term policy priorities - the role of ICSs in improving diagnosis and care pathways across local health systems
• diagnosis: addressing the delays following the pandemic - funding needs - developing early intervention and best practice within primary care - diagnosis in nursing homes
• prevention: awareness of identifiable symptoms and at-risk groups - addressing regional and ethnic inequalities in diagnosis and care access - memory assessment and tackling clinic backlogs
• R&I: priority areas for dementia research and advancing clinical trials - key issues for regulation and assessment - funding for developing innovative treatments and detection
• collaboration: assessing the potential of a vaccines taskforce approach to dementia to support development going forward - opportunities for increasing the role of patient voices in care treatment
• priorities going forward: regulatory approval for new treatments - adoption in the NHS - financial challenges - improving early diagnosis to boost access to effective treatment

Keynote speakers who have agreed to take part include: Amanda Partington-Todd, Deputy Director, Adult Social Care, Care Quality Commission; Peter Bagshaw, Clinical Lead, Mental Health and Dementia, NHS Somerset; David Thomas, Head, Policy and Public Affairs, Alzheimer’s Research UK; and James White, Head, National Influencing, Alzheimer’s Society.

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DSIT; MHRA; and HMPPS.

The proceedings of the conference will be circulated more widely, to Parliamentarians, ministerial offices, and government and regulatory officials with an interest in the issues being discussed. All delegates will also receive a video recording of the conference.

This conference examined key issues for genomics in the UK following the recent announcement of the NHS Genomics Networks of Excellence, which aim to develop innovative approaches to key NHS challenges.

It brought together stakeholders and policymakers to assess the progress and next steps for the Genome UK: 2022 to 2025 implementation plan for England and the NHS Genomic Medicine Service.

Delegates discussed priorities for supporting innovation in genomic medicine and advancing research, as well as opportunities for AI in genomic science and improving patient outcomes.

Discussion examined opportunities for implementation of genomic technologies across healthcare delivery in the NHS and more widely, including personalised medicine and predictive diagnostics.

Delegates assessed progress in adopting and embedding genomic science in the NHS so far, with discussion on the way forward for medicine optimisation and pharmacogenomics, and building patient pathways and models of care to enable improved patient access to innovative diagnostics and treatments. They also considered issues around data, including security and growing diversity in the UK Biobank, patient records and digital maturity in the health system.

The agenda looked at enablers for achieving the application of innovative approaches routinely in the NHS, and the way forward for putting them in place. Areas for discussion included advancing collaboration and investment, ensuring security, and the necessary regulation frameworks.

Further sessions assessed priorities for supporting the workforce with developments surrounding genomics and its application in the NHS, including next steps for education and training, and building capacity and involvement with research.

We are pleased to have been able to include keynote sessions with: Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics, NHS England; Dr Rich Scott, Chief Executive Officer, Genomics England; and Dr Kate Tatton-Brown, Consultant in Clinical Genetics, St George’s Healthcare NHS Trust.

Overall, areas for discussion included:

• NHS Genomics Networks of Excellence: collaboration between the NHS, academics, genomics labs and the third sector - innovative approaches to addressing challenges - utilising funding and cutting-edge technologies
• genome sequencing: the future outlook of whole genome sequencing for detection and diagnostics to improve healthcare outcomes - options for predictive healthcare models - next steps for advancing research
• data: supporting R&I within UK biobanks and the secure handling of health data - data and cybersecurity - access to data and collaboration - approaches to clinical trials - regulation
• pharmacogenomics: tackling adverse drug reactions - medicines optimisation - developing personalised therapies - workforce education and training
• patient accessibility: priorities for improving data diversity in the UK Biobank - reducing health inequalities - supporting patient understanding and awareness of genomics in healthcare - clinician engagement
• workforce: supporting the role of the workforce in implementation of genomics medicine across health services - next steps for education and training

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DSIT; MHRA; OLS; UKHSA; DoH, ROI; DBT; Department for the Economy, NI; and the Welsh Government.

This conference discussed next steps for long COVID care and research in England.

Taking place following long COVID services transitioning from the national programme to ICBs in March 2023, delegates discussed priorities for developing effective long COVID commissioning, services and care pathways, as well as options for earlier diagnosis, population health approaches and tackling health inequalities.

It was an opportunity to examine progress made on The NHS plan for improving long COVID services, including next steps for assessment clinics, clinical education, rehabilitation, and improving access to innovative treatments.

The agenda brought out latest thinking on characteristics and risk factors associated with long COVID, and developing the role of patient experience in informing decision-making processes.

Sessions also assessed progress in long COVID research following investment in recent years, looking at priorities for building the evidence-base, and for advancing research and development of long COVID treatments, including next steps for the use of data and AI.

Further areas for discussion included addressing challenges with clinical trials and options for improving participant recruitment.

We are pleased to have been able to include keynote sessions with: Dr Melissa Heightman, Clinical Lead, Post-COVID Services, University College London Hospitals NHS Foundation Trust; Professor Paul Elliott, Chair, Epidemiology and Public Health Medicine, Imperial College London; and Dr David Strain, Senior Clinical Lecturer, University of Exeter.

Overall, areas for discussion included:

• Latest developments: assessing trends, key issues and progress - priorities from the long COVID plan - the role and impact of assessment clinics
• Care pathway for long COVID: the role of integrated care systems in commissioning and overseeing post-COVID services - utilising population health approaches
• Earlier diagnosis: evaluating access to services - tackling health inequalities - clinician education - improving service referral
• Living with long COVID: access to psychological therapies - self-management plans and peer support - rehabilitation and its impact on employment
• Clinical research: developing understanding of long COVID symptoms - addressing challenges in clinical trials - improving participation - building the evidence-base
• Data studies: understanding the prevalence of long COVID - use of big data studies to identify vulnerable populations - identifying and addressing health inequalities - the role of AI
• Innovative treatments: improving patient outcomes - prediction and prevention - applying latest developments in research - opportunities for advancing treatment development - potential for repurposing drugs approved for other conditions

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; MHRA; UKHSA; UKSA; DLUHC; DWP; HM Treasury; NAO; The Scottish Government; and the Welsh Government.

This conference discussed next steps for patient records in the NHS and the use of patient data in England.

It was an opportunity for stakeholders and policymakers to discuss priorities for the rollout of the Federated Data Platform, introduced by NHS England last year aiming to support health and care organisations utilise data and work together to understand patterns, solve problems and plan services for their local population.

Delegates assessed how to incorporate lessons learnt from pilot case studies, and next steps for building public trust and awareness, with concerns over transparency in data, including the future of data-sharing in light of the NHS partnership with private industry to support delivery of the platform.

The agenda looked at linked issues around data protection and security, and latest thinking on addressing challenges around anonymisation and accessibility of data, as well as priorities for partnership-working and the role of new approaches to data in enabling innovative healthcare solutions and collaborative working.

With the Spring Budget announcing plans for improving NHS productivity through electronic patient records and updated IT systems, the conference discussed the future of data management, looking at priorities for trust and transparency, delivering effective integrated data, and tackling challenges at NHS trust level, including digital maturity.

The agenda looked at the impact of inclusion of GP records on the NHS App, and the future of patient involvement with their healthcare, including how to increase public understanding of their records, as well as priorities for protecting and supporting vulnerable groups. Delegates also discussed implications for efficiencies for GP surgeries and access to results.

Clinical research was a key focus in the agenda, examining initiatives aimed at improving the accessibility of patient data to support innovation, development of new medicines, and advances in treatment. We also expected discussion on strategies for improving diversity and inclusion relating to sources of health data.

Following the Goldacre review, further sessions looked at the development of Secure Data Environments, with discussion on next steps for digital infrastructure to make best use of data-driven research.

We are pleased to have been able to include keynote sessions with: Louise Greenrod, Deputy Director, Data Policy, Department of Health and Social Care; Dr Nicola Byrne, National Data Guardian; and Professor Ben Goldacre, Director, The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford.

Sessions in the agenda included:

• priorities for the Data Guardian: trust and transparency in data use across the NHS
• public confidence: data sharing and the relationship between healthcare professionals and patients
• the Federated Data Platform:
  
  • next steps for development and rollout - data management and integration - the role of the private sector - delivering effective nationally-integrated data
  • learning from the pilots - addressing key issues at NHS trust level - tackling variation in levels of digital maturity
• the NHS App: examining impact so far of record-sharing on patient engagement with their healthcare and GP efficiency
• data for research:
  
  • improving availability and impact on innovative healthcare solutions and health outcomes - priorities for partnership working - improving diversity and inclusion in sourcing health data
  • secure Data Environments - data protection and security - privacy and transparency - building public trust in data research use
• policy: the future for patient records in the NHS and the use of patient data in England

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; MHRA; UKHSA; OLS; DSIT; DBT; ICO; NAO; HMPPS; GLD; DWP; UKSA; Defra; DLUHC; DoH, ROI; HMRC; The Scottish Government; and the Welsh Government.

This conference assessed priorities for medicines access, supply and pricing in the UK.

It followed the publication of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) agreement between the DHSC, NHS England and ABPI.

Launching in January 2024, the five-year scheme aims to control expenditure on branded medicines, support financial sustainability in the NHS, promote better patient outcomes, and boost growth in the UK life sciences industry. However, concerns have been raised by generic manufacturers about the potential impact of the new agreement on the supply of generic medicines in the UK. 

Stakeholders and policymakers assessed the impact of the VPAG scheme on different stakeholders, looking at approaches for improving patient access to the latest medicines and treatments, with discussion on price control mechanisms, developing targets and monitoring progress, transparency and public engagement, and identifying potential challenges for medicines supply and affordability.

It was also an opportunity to discuss the way forward for delivering growth and innovation in the UK life sciences industry, including implications of VPAG on the economy, future outlook for patient access to advanced medicinal products as the scheme commits to exploring innovative payment models, and developing frameworks for dynamic collaborations between government and industry.

Further sessions discussed current medicine shortages across the UK, options for mitigating the impact of shortages, tackling issues of medicines availability across the global supply chain, strategies to strengthen supply and resilience, and safeguarding the supply of generic medicines in the UK.

We are pleased to have been able to include keynote sessions with: Kim Assender, Director of Commercial Policy and Analysis, Association of the British Pharmaceutical Industry; David Watson, Executive Director of Patient Access, Association of the British Pharmaceutical Industry; Anusha Foy, Partner and Head of Life Sciences Regulatory Solutions Practice at KPMG; and Elizabeth Hampson, Partner, Deloitte.

Overall, sessions in the agenda included:  

• VPAG: key implications for industry, patients and value for money in the NHS - resources, infrastructure and investment needed for successful delivery - priority areas for scheme implementation
• progress: identifying areas for improving patient outcomes - transparency - assessing options for monitoring to track and evaluate progress - coordinating policy to drive investment and innovation
• finance: assessing the financial sustainability of NHS spending on medicines through price control mechanisms - the medicines sales growth cap - pricing of newer and older medicines and exemptions 
• patient outcomes: approaches for improving patient access to medication and treatment - examining what the VPAG scheme means for patient access to innovative medicines - addressing inequalities
• medicines supply: addressing and mitigating medicine shortages - options for tackling key issues in the supply chain - building resilience and stability across the supply chain - continuity in patient care
• technology and innovation:
  
  
  
  • utilising latest technology and data-driven approaches, such as the Patient Support Programme - potential benefits for improving patient access to novel treatments and management
  • assessing the outlook for advanced therapy medicinal products, regulatory pathways and payment models - priorities for delivering commitments to supporting innovative approaches
• life sciences: coordinating policy to support investment and attract product launches to the UK - the role of VPAG in the economic growth of the UK life sciences industry - boosting the UK’s international competitiveness in the life sciences sector

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DoH, NI; MHRA; UKHSA; DBT; Department for the Economy, NI; GLD; HM Treasury; and the Welsh Government.

This conference focused on maternity services in England, and priorities for improving quality and care outcomes.

Stakeholders, regulators and policymakers assessed progress and next steps for making services safer, more personalised and equitable, in line with aims outlined in NHS England’s Three year delivery plan for maternity and neonatal services published in March 2023. The discussion took place following Oxford University’s Maternal mortality 2020-2022 report published in January 2023, highlighting a near 20-year high in deaths during pregnancy or soon after childbirth.

Delegates discussed the Government’s response to the Kirkup Review and the earlier Ockenden Maternity Review, looking at creation of the maternity and neonatal oversights group, recent funding for maternity workforce expansion and specialist training, as well as the recently launched national initiative to improve safety in maternity care through the new Maternity and Newborn Safety Investigations programme.

It was an opportunity to consider the work of the expert panel appointed by the Health and Social Care Select Committee, with discussion on progress and remaining barriers in areas including maternity care and leadership, safety culture, staff training and whistleblowing, following the Government accepting recommendations from inquiries and reviews.

Addressing challenges for the maternity workforce was also a focus, following the announcement of £35m in the Spring Budget to fund specialist training for staff and additional midwives to listen and act on women’s experiences to improve care. Further discussion was expected on next steps for developing and sustaining a culture of safety throughout patient experience, and the role of integrated care systems in driving improvements and leadership at the local level.

The agenda looked at developments in the use of data to monitor performance, improve care, tackle variation and track progress in meeting ambitions for transformation.

Further sessions discussed priorities for addressing health disparities during pregnancy and in post-partum care following the Black maternal health report, tackling the relationship between infant mortality and health inequalities, and the Government’s £50m funding for maternity disparities research outlined in the Women’s Health Strategy for England.

We are pleased to have been able to include keynote sessions with: Sandy Lewis, Associate Director, Maternity Investigation Programme, Maternity and Newborn Safety Investigations; Gill Walton, Chief Executive, Royal College of Midwives; and Nicola Wise, Director for Secondary and Specialist Healthcare, Care Quality Commission.

Overall, areas for discussion included:

• policy: assessing and evaluating the strategic direction for improving standards and quality in maternity care
• inequalities: identifying and addressing causes of disparities in maternity care - next steps in driving equality in maternity care
• safety standards: priorities for improving the safety of maternity services - communications between services - promoting best practice - knowledge sharing - use of data - listening to patients
• workforce: priorities for education, training and professional development - tackling challenges in recruitment and retention - developing and maintaining positive cultures
• improving care: addressing inequalities in accessibility and information - mental health support - developing personalised care plans for pregnant women
• continuity of care and safeguarding: options for continuing care received during pregnancy - supporting new mothers - safeguarding newborns
• priorities going forward: quality and safety of services - improving the outlook for maternity services - safety and regulation - the future of government funding

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from CQC; DHSC; Department of Health, NI; DLUHC; HMPPS; The Scottish Government; and the Welsh Government.

This conference focused on the independent sector and its role in healthcare delivery into the future.

Stakeholders and policymakers examined next steps for collaboration on capacity and innovative approaches to addressing backlogs in elective care, following the Government’s Elective recovery taskforce: implementation plan, which incorporates the independent sector as a key component in moving services forward.

The agenda also looked at the outlook for commissioning services, looking at the opportunities and issues following the recently launched Provider Selection Regime.

Those attending considered options for wider collaboration between the NHS and independent providers, and priorities for the independent sector in tackling elective care backlogs and supporting recovery moving forward. They also discussed the relationship between independent sector and integrated care systems.

Further sessions in the agenda focused on patient choice and accessibility, and supporting the workforce, as well as priorities for regulation and standards.

There was also discussion on alternative options for policy on the scope and nature of independent sector involvement in healthcare, and implications for the NHS, private providers and patients.

We are pleased to have been able to include keynote sessions with: David Hare, Chief Executive, Independent Healthcare Providers Network; and James Roach, Managing Director, Conclusio.

Overall, areas for discussion included:

• elective recovery backlogs: examining the progress of the Elective recovery taskforce: implementation plan - capacity of the independent sector to meet key targets
• collaboration: innovative approaches and options - best practice - case studies - priorities going forward
• commissioning: changes to commissioning - navigating ICSs and local models of healthcare - impact of the Provider Selection Regime on the independent sector
• regulation: next steps for risk assessment - approaches to regulating independent provider care services - continuity of quality care
• workforce: addressing retention and recruitment challenges - options for apprenticeships, training and education - priorities for long-term national workforce planning
• patients: choice and accessibility - improving patient understanding of their choices - addressing inequity of care provision
• next steps: future policy outlook for the independent sector and its role in healthcare delivery - policy options going forward

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DHSC; DoH, NI; OLS; DBT; NAO; and The Scottish Government.

This conference discussed next steps for NICE in delivering innovation and supporting clinical practice in health and social care in England.

It brought stakeholders together with policymakers to evaluate progress on key ambitions outlined in the NICE Strategy 2021 to 26, and next steps for guideline development following publication of Transforming NICE.

Delegates discussed the role of NICE in the development of new approaches and models of healthcare, including:

• developing guidance around integrated care following the Health and Care Act 2022
• new preventative and personalised models of healthcare being developed as part of the Major Conditions Strategy
• addressing NHS challenges, including recent guidance around the use of virtual wards to support capacity within hospitals

Discussion considered use of real-world evidence, new approaches to health technology evaluation, and improving patient access to innovative treatments.

Further sessions looked at NICE’s future role in improving patient outcomes, tackling health inequalities, providing value for money and safeguarding the use of new technologies.

We are pleased to have been able to include keynote sessions with: Dr Clare Morgan, Director of Implementation and Partnerships, NICE; Dr Sarah Byron, Programme Director, Devices, Diagnostics and Digital, NICE; and Sarah Jenner, Principal, IQVIA.

Overall, areas for discussion included:

• priorities for 5-year strategy: next steps and key issues for strategy delivery - driving development and adoption of innovative and cost-effective health technologies to improve patient outcomes
• transforming NICE: exploring ways to better meet user needs and adapt to changes in healthcare - improving care while keeping it affordable and effective 
• real-world evidence framework:
  
  • utilising data for insight into healthcare delivery, patient experience and intervention outcomes - progress and next steps for research and innovation
  • ensuring that data-driven approaches are safe and reliable in order to enable use in real-world situations - measuring impact - implementation of Secure Data Environments (SDEs) 
• evaluation: taking forward new approaches to assessing health technology - priorities for supporting efficient adoption of new developments - improving patient access to medicines
• innovation: utilising new technologies and data-driven approaches to improve outcomes - options for preventative and personalised care models - developing approaches for the use of AI
• reducing pressures: the supporting role of NICE guidelines in tackling backlogs in the NHS - priorities for virtual wards, care pathways and community care
• collaboration: strategies and frameworks for increased co-working between the NHS, the research industry and academia
• social impact: developing guidelines to better support key societal priorities - health inequalities - patient access and safety - increasing treatment options across a diverse range of conditions

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DoH, NI; MHRA; OHID; UK NSC; DBT; GLD; HMPPS; HM Treasury; The Scottish Government; and the Welsh Government.

This conference examined the future for clinical research in the UK.

It followed the Lord O'Shaughnessy Review on Clinical Research and the Government’s response in December 2023, accepting in principle its proposals for addressing key challenges in conducting trials in the UK and transforming the UK commercial clinical trial environment.

Stakeholders and policymakers discussed next steps for implementation of recommendations from the review, including reducing regulatory burdens, improving clinical trials and participation by both clinicians and the public, developing targets, reporting and public engagement, and putting in place a comprehensive framework of metrics for government ambitions for clinical research.

The conference was an opportunity to discuss innovative approaches to advancing UK clinical research leadership internationally, and to meet ambitions in The Future of UK Clinical Research Delivery 10-year vision as activity in the life sciences sector recovers from the pandemic. Areas for discussion included strategies for transformation of the research environment and resolving key challenges in conducting commercial clinical trials.

Delegates assessed the future for innovation, including utilising AI for medical discoveries, delivery of clinical trials, and supporting patient and clinician engagement with research.

Attendees examined advances in the use of data, and its security and management, to improve the outcomes of clinical trials, as well as approaches to improving the administration and infrastructure for delivery of clinical trials.

Further sessions in the agenda assessed new approaches to workforce and skills development, improving accessibility and participation within research, including the use of virtual studies, and overcoming current challenges in delivering research in healthcare settings closer to the community.

We are pleased to have been able to include keynote sessions with: Emma Lowe, Head of Clinical Research Delivery, Science, Research and Evidence Directorate, DHSC; Becky Purvis, Director of Policy and Partnerships, Health Research Authority; Dr Rachel Armstrong, Principal, Head of Real World Database Studies UK, IQVIA; and Andrea Manfrin, Deputy Director of Clinical Trials and Investigations, MHRA.

Sessions in the agenda included:

• UK clinical research: progress and priorities for recovery, innovation and transformation
• clinical trials: 
  
  • efficiency and delivery - regulation and standards - growing the research workforce
  • increasing participation and diversity - patient and clinician engagement - building trust and transparency in research
• innovation:
  
  • implementation and development to improve clinical research outcomes - AI in clinical trial design - wearable technology and remote monitoring - digitalisation
  • secure data environments - use of real-world data - improving data management
  • improving access - raising public awareness - developing the NHS app
  • funding and R&D priorities - increasing collaboration between the NHS and research industry
• policy: next steps for delivering long-term ambitions for clinical trials and life sciences research

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DoH, NI; CPRD; MHRA; DBT; OLS; UKHSA; IPO; and the Welsh Government.

This conference examined the way forward for achieving net zero emissions in the NHS by 2040, assessing progress so far, outstanding issues and next steps for developing environmentally sustainable healthcare.

As stakeholders work to develop effective strategies and the New Hospital Programme establishes a more standardised approach, it was an opportunity to discuss latest thinking around key issues for meeting targets, including building and facilities design, low-carbon technologies, back-up power, local grid capacity, air-flow and heating.

Delegates discussed approaches to establishing net zero benchmarks, looking at increasing the availability of data to build the evidence base, support monitoring and strategies moving forward.

They also considered examples of best practice in assessing cost-effectiveness whilst maintaining patient safety and care quality, and implications for development of policy and guidance on benchmarks and how decarbonisation targets are met.

Discussion examined the work of integrated care systems in implementing their green plans, including lessons and best practice around collaboration - and the way forward for progressing strategic, local approaches to sustainable healthcare.

We expected discussion on innovation in key areas for energy use reduction, including in ventilation to maintain indoor air quality with minimal energy consumption, and in sustainable heating and cooling in healthcare facilities.

Further sessions explored best practice sustainable clinical care procedures, and priorities for waste reduction, including in areas such as single use plastic, and waste management in the NHS following the NHS clinical waste strategy.

We are pleased to have been able to include keynote sessions with: Lord Markham, Parliamentary Under Secretary of State, Department of Health & Social Care (pre-recorded contribution); Chris Gormley, Chief Sustainability Officer, NHS England; Dr Hayley Pinto, Education and Training Lead, The Centre for Sustainable Healthcare; Sam Willitts, Head of Sustainability, Integrated Care System, North Bristol NHS Trust; Simon Barry, Lead, National Respiratory Health Implementation Group Wales; and Clive Nattrass, Programme Manager, NHPower.

Overall, areas for discussion included:

• The net zero benchmark: examining steps being taken to deliver sustainability and net zero targets across the NHS estates - assessing priorities and approaches going forward
• Integrated care boards: exploring how net zero targets can be reached at ICB level - examples of successes
• Waste reduction: next steps for incorporating sustainability through the New Hospital Programme - with eco-friendly designs - energy-efficient tech - sustainable materials
• Cost-effectiveness and patient safety: ways to balance cost-effectiveness with maintaining patient safety and quality of care

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who are due to attend from the CCS; CQC; DBT; Defra; DESNZ; DHSC; HSE; Isle of Man Government; The Scottish Government; and the Welsh Government.

This conference focused on next steps for developing respiratory health services and improving lung health in England.

It was an opportunity for stakeholders and clinical leaders to assess the delivery of respiratory health services over the winter and lessons learned for future planning.

Delegates examined the preparation and implementation of NHS England’s Winter Plan 2023/24 as well as the impact of NICE guideline updates, including the use of virtual wards for acute respiratory infection. They considered key issues for NHS service delivery, including priorities for addressing winter pressures and co-circulation of flu and COVID-19.

The conference also examined the inclusion of respiratory health within the interim report of the Major Conditions Strategy.

Areas for discussion included priorities for improving health outcomes, public health and prevention, managing multiple health conditions, addressing health inequalities, and key areas for innovation and diagnostics.

Delegates also assessed latest thinking on the way forward for reducing smoking and managing vaping within the population, following the publication of the Khan review: making smoking obsolete, the Government’s decision to ban the use of disposable vapes and the recent DHSC consultation on Stopping the start: our new plan to create a smoke free generation.

Further sessions considered addressing links between chronic respiratory disease and air pollution, and looking at effects of current measures and options for the future.

We are pleased that keynote speakers included: Dr Jonathan Fuld, Consultant Physician and National Clinical Director for Respiratory Disease, Cambridge University Hospitals NHS Foundation Trust; Henry Gregg, Director of External Affairs, Asthma + Lung UK; and Chair, Taskforce for Lung Health; Larissa Lockwood, Director of Clean Air, Global Action Plan; Katie Hannant, Clinical Respiratory Lead for CYP, NHS Frimley Integrated Care Board; and Professor Robert West, Professor of Health Psychology and Director of Tobacco Studies, University College London.

Overall, areas for discussion included:

• policy: evaluating the current climate for respiratory health services - priorities for improving treatment and care - managing multiple conditions - improving health outcomes
• winter and acute care: respiratory health service pressures - lessons and approaches to inform future preparedness - vaccination programmes - the role and impact of virtual wards
• smoking: recommendations from the Khan review and the outlook for policy plans for a smoke-free generation - next steps for reducing smoking - the ban on disposable vapes
• air pollution: assessing strategic options for tackling air pollution and its impact on chronic respiratory disease - assessing effects of current measures and options for future lung health
• prevention: latest thinking on reducing risk and tackling health inequalities - vaccination and supporting vulnerable groups - clinical assessment - increasing patient and public awareness
• diagnosis and innovation: personalised care and management of long-term conditions - new approaches to identifying and diagnosing patients - the role of data and opportunities through AI

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DfT; DHSC; DoH, NI; DWP; HM Treasury; HSE; MHRA; and NAO - as well as parliamentary pass-holders from the House of Lords.

This conference focused on next steps for prevention, diagnosis and treatment of cancer in England.

It was an opportunity for stakeholders and policymakers to discuss priorities for tackling the backlog in cancer services following the Elective recovery taskforce: implementation plan published in August 2023.

Delegates considered the way forward for improving cancer screening and diagnosis, including the work of cancer alliances in helping meet patient demand, as well as enhancing healthcare infrastructure and building resilience in the cancer workforce.

Those attending also assessed priorities for improving patient outcomes, looking at best practice and next steps for personalised and informed approaches to treatment, prevention and screening, following the results of the 10-Year Cancer Plan call for evidence, and as the Major Conditions Strategy is developed.

Further sessions examined the future outlook for improving patient access to treatments and latest technology including AI, and making the UK an attractive testbed for innovative cancer research and treatments following the Cancer Healthcare Mission launched from the Life Sciences Vision.

We are pleased to have been able to include keynote sessions with: Dr Colin Wilson, Deputy Director, Office for Life Sciences; Professor Richard Sullivan, Director, Institute for Cancer Policy, King’s College London; Dr Tom Roques, Vice President, Clinical Oncology, The Royal College of Radiologists; and Professor Stephen Duffy, Professor for Cancer Screening, Wolfson Institute of Population Health.

Overall, areas for discussion included:

• 10-Year Cancer Plan: assessing findings from the call for evidence - impact of rolling the long-term plan into the Major Conditions Strategy 
• Tackling the backlog in England: options for increasing capacity, such as partnerships - infrastructure for cancer services - development of prevention strategies 
• Screening and early diagnosis: investment in the cancer workforce and its growth - improving effectiveness of screening services - support for clinical research - next steps for genomic sequencing
• Improving patient outcomes: integrating pre-treatment services to treatment providers - working with ICSs to meet local need - the role of cancer alliances - access to mental health support
• Maximising research impact: the Cancer Healthcare Mission - rolling out new models of care - implementation of innovative technology - improving data on rehabilitation services
• Access to innovative treatments: addressing affordability - regulatory challenges - the impact of inequalities on cancer treatment - making the UK a testbed for innovation care and clinical trials
• Personalised care: assessing developments around patient-centred care - utilising data and the role of digital technology and AI - improving patient access to innovative cancer treatments

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from MHRA; UK NSC; DHSC; CQC; OLS; UKHSA; DBT; FSA; HMPPS; HM Treasury; ONS; and Audit Wales; as well as parliamentary pass-holders from the House of Lords.

This conference discussed next steps for tackling antimicrobial resistance in the UK.

It was a timely opportunity for stakeholders and policymakers to examine priorities for the new AMR action plan expected next year, with the current 5-year action plan coming to an end.

Delegates reviewed progress in the UK’s 20-year vision for antimicrobial resistance, development of new antibiotics, and the impact of funding set out in the Global AMR Innovation Fund to advance early development of new antibiotics.

Further areas for discussion included innovation and opportunities for the use of new technologies such as AI in streamlining the development of new antibiotics, international collaboration and next steps for UK international leadership in tackling AMR, and priorities for the UN General Assembly high-level meeting on AMR taking place this year.

Further sessions looked at best practice and priorities for surveillance, and the role of integrated care systems in local coordination, prescribing and patient awareness.

We are pleased to have been able to include keynote sessions with: Professor Dame Sally Davies, UK Special Envoy, Antimicrobial Resistance; Morwenna Carrington, Deputy Director, UK Health Security, DHSC; Deborah O'Neil, Chief Executive Officer, NovaBiotics; and Professor Lord Darzi of Denham, Chair, The Fleming Initiative.

Overall, areas for discussion included:

• the current state of AMR: progress so far with the UK 5-year AMR action plan and priorities beyond
• healthcare delivery: the role of NHS institutions in addressing AMR and enhancing patient safety - plans for improving infection prevention and control measures within healthcare facilities
• research: emerging resistance mechanisms - surveillance methods - innovative approaches to treatment - investment priorities to support development of new antibiotics and diagnostic tools
• pharmaceuticals: incentivising drug development and promoting responsible antibiotic use - latest thinking on addressing issues of profitability and regulatory hurdles for antibiotic development
• prescribing:
  
  • developments, responsibility and best practice
  • education, information and supporting behaviour change of both healthcare providers and the public - strategies for implementing antimicrobial stewardship programs
• collaboration: improving joint working between government, healthcare and the pharmaceutical sector - strategies for policy, government support, regulatory reform and international relationships

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DAERA, NI; DBT; Defra, DHSC; FSA; FSA, NI; FSS; HM Treasury; HSE; MHRA; VMD; The Scottish Government; and the Welsh Government.

This conference focused on priorities for improving urgent and emergency care services in England.

It was an opportunity to examine progress and next steps for:

• the Delivery plan for recovering urgent and emergency care services - published by NHS England in January 2023
• the Re-envisioning urgent and emergency care report - published by the NHS Confederation in December 2022

Stakeholders and policymakers assessed key priorities, including implementation and investment of the delivery plan, and the way forward for reducing waiting times and improving patient outcomes.

Further sessions looked at issues surrounding the workforce and service capacity, speeding up patient discharge, next steps for the same day emergency care policy, and the future outlook for virtual wards.

We are pleased to have been able to include keynote sessions with: Ashley McDougall, Director, Health Value for Money, National Audit Office; Dr Adrian Boyle, President, Royal College of Emergency Medicine; Mike Hearne, Managing Director, Taurus Healthcare; Lauren Parry, Medical Director, Taurus Healthcare; and a pre-recorded contribution from Miriam Deakin, Director of Policy, NHS Providers.

Overall, areas for discussion included:

• the delivery plan: progress, trends and challenges in delivering sustainable recovery of urgent and emergency care in England - priorities for improving accessibility
• workforce:
  
  • what will be needed to deliver the aims of the NHS Long Term Workforce Plan for emergency care
  • strategies for growing the emergency care workforce, as well as training, professional development and retention
  • priorities for supporting staff - addressing challenges for the workforce that are specific to emergency care
• waiting times: enabling same day emergency care targets to be met - latest thinking and best practice in effective hospital design - developing capacity and flow - priorities for funding
• hospital bed occupancy: addressing issues with speeding up patient discharge - the role of social care and options for expanding care in the community - progress in delivery of virtual wards
• capacity and accessibility: the role of Integrated Care Systems in developing effective pathways for improving capacity - involvement of the independent sector
• quality: next steps for driving up standards - enabling long-term sustainable system recovery - priorities for aligning needs in emergency care with wider policy developments and initiatives

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DBT; DHSC; HM Treasury; Home Office; The Scottish Government; and the Welsh Government.

This conference focused on next steps for adult social care in England.

It ibrought stakeholders and policymakers together to discuss key priorities for service improvement in the context of the Next steps to put People at the Heart of Care policy paper published in April, as well as the Government’s response to the House of Lords Adult Social Care Committee’s report earlier this year.

Delegates discussed options for addressing key issues including improving performance, funding models, developing service user choice and access to care, and increasing workforce capacity.

Attendees considered priorities for addressing workforce challenges and options for improving skills within the sector, with the Government expected to publish a ‘care workforce pathway for social care’ later this year.

Further sessions looked at achieving effective integration of social care within ICSs, as well as the way forward for delivering accountability and quality social care, and alternative and innovative models of care delivery.

We are pleased to have been able to include keynote sessions with: Baroness Andrews, former Chair, House of Lords Adult Social Care Committee (pre-recorded presentation); Vicky Davis, Director, Local Government Value for Money, National Audit Office; Professor Martin Green, Chief Executive, Care England; and Stuart Hoddinott, Senior Researcher, Institute for Government.

Overall, areas for discussion included:

• policy: looking at progress in reform commitments so far - implementing the social care white paper - assessing the impact of recent reports on the social care policy landscape
• funding: current outlook and approaches to funding and performance of adult social care in England - potential for increased investment
• different approaches: options for alternative ways of providing care - future role for the private sector - implications of interventions such as the Archbishops’ Covenant for England
• workforce: addressing capacity and burnout - recruitment and retention priorities - supporting unpaid carers - developing skills in the sector
• integrated care: effective integration of social care within ICSs - the role of ICSs in the commissioning of care services going forward and reducing inequalities - developing innovative care delivery
• quality of care: how best to improve accessibility and quality of care within the NHS - the role of inspections and accountability in ICSs - developing personalised care and choice for service users
• health disparities: assessing potential geographical variation in adult social care services - addressing national disparities and reducing health inequalities

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; GLD; HMPPS; Home Office; ICO; UKSA; and The Scottish Government - as well as parliamentary pass-holders from the House of Lords.

This conference focuseed on key priorities and next steps for dentistry in England.

Delegates discussed next steps for service recovery following pandemic disruption, with funding from the Government last year aimed at managing backlogs.

Policymakers and dentistry stakeholders assessed findings from the Health and Social Care Select Committee inquiry published in the summer, which looked at access to NHS dentistry, the Dental Contract and the workforce. Sessions in the agenda looked at next steps, including issues around workforce retention and the future sustainability of the profession.

The conference was also an opportunity to discuss the 2022-2023 contract reform agreements, focusing on impact so far and the way forward as integrated care systems implement their responsibilities for commissioning dentistry services, as well as the role of dentistry within development of ICSs, and prospects for further development and support for dentistry.

Delegates looked at priorities for delivering efficient oral healthcare and the wider drive to improve prevention, including the impact of pooled budgets, and priorities for building dental teams.

We are pleased to have been able to include keynote sessions with: Stefan Czerniawski, Executive Director, Strategy, General Dental Council; Professor Rebecca Harris, Honorary Consultant in Dental Public Health, University of Liverpool; Edward Jones, Senior Policy Advisor, ICS Network, NHS Confederation; and Wendy Crew, Advisor, Primary Care Commissioning.

Overall, areas for discussion included:

• service restoration: addressing backlogs, in balance with safety and infection control - balancing routine appointment catch-up with delivering emergency dental care - the impact of funding
• dental contract reform: possible outcomes and implications for the sector - providing clarity following prototype practices being dropped - impact of the pandemic
• workforce: assessing reform to dentistry education and training - progress since the Advancing Dental Care Review - concerns around retention and the future sustainability of the profession
• integrated care: the role of dentistry within ICSs, as well as the wider focus on prevention - changes to commissioning - the impact of pooled budgets on dentistry
• accessibility: identifying and overcoming barriers to access - improving the availability of services - addressing health inequalities
• integrated oral care: the role of dentistry in preventative healthcare - the impact of commissioning changes
• professional regulation: the priorities and outlook for reform for the dentistry profession - options for streamlining and efficiency - standards and support for the sector

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; Department of Health, ROI; HM Treasury; and NAO.

This conference discussed the future for professional healthcare regulation in the UK.

Stakeholders and policymakers considered latest developments and next steps for regulation with legislative reform underway affecting the General Medical Council, and with the Nursing and Midwifery Council and Health and Care Professions Council next to go through a similar process.

It was an opportunity to discuss the approach for legislative reform at the GMC and what this means for the other regulatory councils, as well as opportunities and challenges presented, and the timelines for future reform.

Delegates assessed proposals for changes to fitness to practise regulation systems, the proposed three-tiered system, and considerations for adverse health going forward.

Further sessions looked at priorities for ensuring that reform can ensure safety for patients and delivery of quality care in ways that also meets the needs of a modern workforce. Delegates also discussed the wider landscape for professional regulation following the pandemic.

We are pleased to have been able to include a keynote session with: Phil Harper, Deputy Director, Professional Regulation; and Sean Marchesi-Denham, Deputy Branch Head, Professional Regulation, Department of Health and Social Care. There will be further contributions from: Tim Aldrich, Assistant Director, Regulatory Reform, General Medical Council; Christine Elliott, Chair of Council, Health and Care Professional Council;Thomas Reynolds, Head of Policy and Strategic Communications, Medical Defence Union; and Alan Clamp, Chief Executive, Professional Standards Authority for Health and Social Care.

Overall, areas for discussion included:

• reform: stakeholder perspectives on proposals - changes in the approach to regulation - developing an overarching set of criteria for regulation - improving regulatory efficiency
• workforce: developing standards and programmes to support regulated workforce professionalism and delivery of high quality care - preparing the workforce for new healthcare models 
• leadership: the future for regulation of health leaders - what successful leadership and development of system-level working looks like - addressing variation - senior-level education and training
• adapting to change: ways regulation can respond to changes affecting the workforce - increasing workload - growth in digital innovation - types of conditions and co-morbidities 
• patient safety: aligning reform with patient safety policy - developing the role of regulation in promoting safe practices and improving workforce culture - impact of the Ockenden report
• streamlining regulatory structures:
  
  • developing effective frameworks and processes to support decisions on streamlining - ensuring capacity for any proposed changes to be effectively delivered
  • key opportunities for data-sharing between regulators - avoiding duplication and tackling logistical challenges
• fitness to practise: implications of reform for public safety, health and wellbeing - data use and evidence - tackling issues found to be disproportionately affecting ethnic minority staff
• integration: the role of regulation in supporting ICS delivery as health professionals work closer in more integrated healthcare
• indemnity: tackling increasing costs of claims - addressing resource challenges - key priorities for reforming the regulatory process - improving quality of care

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the CQC; Department of Health, ROI; DHSC; HSE; MHRA; NAO; The Scottish Government; and the Welsh Government.

This conference focused on the future of mental health services and prevention in England.

It was an opportunity to discuss priorities as the previously announced 10-year Mental health and wellbeing plan is replaced with the inclusion of mental health within the recently published Major Conditions Strategy.

Delegates discussed the strategic focus placed on addressing mental health through the lens of physical health and managing multiple health conditions, as well as latest thinking on developing effective approaches for improving mental health patient outcomes.

Further discussion considered:

• priorities for improving mental health services following the NAO’s progress report published earlier this year, including issues such as waiting times and barriers to care and treatment
• the role of integrated care systems in improving mental health services and prevention programmes in local areas
• options for the promotion of wellbeing in children and young people
• opportunities for prevention programmes and personalised care, and next steps for tackling health inequalities
• the development of apps and digital health tools to support mental health patients

We are pleased to have been able to include keynote sessions with: Dr Ian Davidson, Clinical Lead, Adult Mental Health Crisis and Acute Care, Getting it Right First Time; Sean Duggan, Chief Executive, Mental Health Network, NHS Confederation; Ashley McDougall, Director, Health Value for Money, National Audit Office; and Dr Roman Raczka, President Elect, British Psychological Society.

Overall, the agenda brought out latest thinking on priorities for:

• policy: strategic direction - investment - enabling preventative approaches - improving service delivery
• services: addressing barriers to care and treatment - improving accessibility - reducing waiting times - developing innovative support
• national variation: strategies and best practice - improving patient flow - developing effective pathways
• workforce: supporting growth to meet future demand - retention and recruitment - the role of third sector partners - next steps for training and development
• prevention: the role of the Major Conditions Strategy - tackling inequalities - developing personalised approaches - interventions for children and young people
• health apps: access to therapy - regulation - developing innovative wellbeing support
• integrated care systems: priorities for commissioning - the role of ICSs in improving local services and pathways - developing effective population health approaches and prevention programmes

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; DWP; HMPPS; HM Treasury; Home Office; House of Commons Library; HSE; and ICIBI.

This conference discussed priorities for improving the prevention, detection and treatment of cardiovascular disease (CVD).

It was an opportunity to assess next steps for integrated cardiovascular services as the Government explores innovative approaches to deliver personalised CVD prevention, following the appointment of Professor John Deanfield as Champion for Personalised Prevention.

Delegates examined long-term priorities for improving health outcomes for heart disease patients, following its inclusion as a key condition in the new interim Major Conditions Strategy, expected in its final form in 2024.

We are pleased to have been able to include keynote sessions with Hashum Mahmood, Senior Policy Advisor, Population Health, NHS Confederation; Professor John Deanfield, Professor of Cardiology, University College London; and Dr Aseem Mishra, Clinical Lead for Cardiovascular Disease Prevention, NHS Greater Manchester Integrated Care System (pre-recorded contribution).

Overall, areas of discussion included:

• prevention: next steps for personalised prevention of CVD - efficiently identifying and tracking risk factors - developing integrated cardiovascular prevention services
• intervention: supporting a healthy lifestyle and behaviour change - addressing social determinants of health - utilising data - the role of primary and community care
• detection and diagnosis: boosting public engagement with CVD screening services - options for more intelligent health checks - priorities for funding and resources
• research and technology: enabling adoption of new technologies for CVD diagnosis, care and rehabilitation - priorities for research into treatments
• treatment: improving access to evidence-based treatment - building service resilience and improving efficiency when managing multiple and long-term health conditions
• inequalities: addressing disparities in access to health services for CVD, including regional inequality - further engaging hard to reach groups
• digital health: opportunities for utilising digital health systems to improve access to services - what is required to effectively deliver remote consultations, remote monitoring and telemedicine
• policy: next steps for cardiovascular policy - what more is needed to deliver aims in the Major Conditions Strategy for CVD

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DLUHC; DHSC; HMPPS; and NAO.

This conference focused on the future for the life sciences sector in the UK.

It was an opportunity to examine the Life Sciences Growth package of initiatives launched by the Chancellor earlier this year, and the way forward for supporting life sciences companies to develop and access investment, with the sector identified by the Government as a priority driver of UK economic growth.

Key stakeholders and policymakers examined progress and next steps for the Vaccine Taskforce model approach to tackling health challenges in the UK, following the Life Sciences Vision.

They assessed government investment so far and priorities going forward, including for improving patient access to innovation and collaboration between industry, the NHS, academia and government.

Further sessions looked at key regulatory developments and government plans for implementing recommendations from Professor Dame Angela McLean’s Pro-innovation Regulation of Technologies Review on Life Sciences. Delegates will also discuss priorities for research following Lord O’Shaughnessy’s review on commercial clinical trials in the UK.

We are pleased to have been able to include keynote sessions with: Thomas Lyle, Deputy Director, Office for Life Sciences; Stuart Carroll, Director, Market Access and Policy Affairs, Moderna; and former Member, Vaccines Taskforce; Dr Jennifer Harris, Director of Research and Development Policy, Association of the British Pharmaceutical Industry; and James Roach, Managing Director, Conclusio.

Overall, areas for discussion included:

• Life Sciences Vision: assessing progress so far - identifying focus areas for research and development funding - priorities for channelling investment - next steps for achieving strategic ambitions 
• new taskforce approach:
  
  • harnessing lessons from the development of the COVID-19 vaccine - funding and support for collaboration
  • next steps for tackling health challenges such as obesity, cancer, mental health and respiratory conditions
• support for sector growth: UK life science start-ups and scale-ups - innovation and manufacturing - creating a business environment that enables the sector to help meet healthcare ambitions
• encouraging collaboration: strengthening cross-industry partnerships and knowledge-sharing - overcoming research funding barriers
• regulation: developing an effective UK framework - ensuring safety - priorities for improving patient outcomes and enabling access to innovative treatments, medicines and medical devices
• UK global positioning: priorities for the future UK-EU relationship - opportunities for increasing the attractiveness of the UK to the wider life sciences industry - establishing UK research leadership

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DBT; Department for the Economy, NI; DfE; DHSC; DSIT; GO-Science; HM Treasury; IPO; MHRA; OLS; UKHSA; UKSIN; and the Welsh Government.

This conference focused on the way forward for elective recovery and waiting times in the NHS.

It was an opportunity for key stakeholders and policymakers to examine the Elective Recovery Taskforce Implementation Plan, recently published by DHSC.

Delegates discussed priorities and next steps following last year’s NHS Delivery plan for tackling the COVID-19 backlog of elective care, and the subsequent NAO report Managing NHS backlogs and waiting times in England, expressing concerns that the delivery plan target to end waits of more than 52 weeks by 2025 risks not being met.

It also came with the Health Secretary announcing measures aimed at enabling the private sector to contribute a higher capacity to speed up access to treatment, alongside the launch of new Community Diagnostic Centres.

We are pleased to have been able to include keynote sessions with: Elin Jones, National Programme Director for Elective Recovery, NHS England; Tom Moberly, UK Editor, British Medical Journal; John Hopgood, Head of Acute Care Policy, Independent Healthcare Providers Network; and Dr Latifa Patel, Representative Body Chair and Equality Lead, British Medical Association.

Further sessions in the agenda looked at the role and next steps for the Elective Recovery Taskforce, including priorities for reducing health inequalities in recovery and waiting lists.

It was also an opportunity to discuss key issues for healthcare workers in relation to tackling backlogs and how the NHS Long Term Workforce Plan can be applied to addressing these challenges.

Overall, areas for discussion included:

• the Elective Recovery Taskforce: analysing recommendations in the taskforce’s Implementation Plan - assessing outcomes of the Government’s elective recovery plan
• workforce: addressing capacity and burnout - recruitment and retention priorities - implementing innovative new ways of working
• the private sector: the future role of independent healthcare organisations - parameters and strategies for their involvement in helping relieve waiting list and elective recovery pressures
• quality of care: priorities for improving accessibility, clinical effectiveness, safety and patient experience of elective care - addressing health inequalities and national variation 
• wider healthcare challenges: the future demand of health services - dealing with an ageing population - supporting patients on waiting lists - assessing potential for utilisation of AI

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the CCS; DHSC; Department of Health, NI; Department of Health, ROI; NAO; ONS; UKSA; The Scottish Government; and the Welsh Government.

This conference discussed priorities for improving NHS estates, examining the plans for delivering the New Hospital Programme’s commitment to build 40 new hospitals by 2030.

Delegates looked at developing effective collaboration across the sector and with industry partners to enable innovation and standardisation, as well as aligning NHS estates with net zero goals and mitigating the impact of climate change.

Stakeholders and policymakers looked at involving healthcare professionals in decision-making processes, as well as in the planning and running of the new hospitals, with discussion on investment and funding of the programme, and industry involvement in this.

The agenda included a focus on catering to the needs of patients and staff, including priorities for patient safety, effective risk management, and developing new facilities, essential upgrades and modernisation.

It came as NAO’s progress report found that the Government has not delivered value for money so far and is not on track to meet targets by 2030. It was also an opportunity to assess progress on the wider Health Infrastructure Plan.

We are pleased to have been able to include keynote sessions with Lord Markham, Parliamentary Under Secretary of State, Department of Health & Social Care; Tim Phillips, Director, Health Value for Money Audit, National Audit Office; Dr Latifa Patel, Chair, Representative Body, British Medical Association; and Alan Morrison, Deputy Director, Health Infrastructure and Sustainability, Scottish Government Health and Social Care Directorate.

Overall, sessions in the agenda looked at:

• the New Hospital Programme: progress and developments - key challenges - the direction of policy and implementation
• assessing the NHS estate: current condition and key issues - priorities going forward
• examining the Programme: prioritisation, timing and investment decisions - staff, patient and wider stakeholder issues and engagement - meeting the demands of the future
• VFM: value for money and the New Hospital Programme
• implementation: project management, partnerships and the supply chain - priorities for innovation, and embedding safety, sustainability, and future-proofing - managing the transition
• policy: next steps for delivering new hospitals and wider transformation within the NHS estate

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the Cabinet Office; CCS; DHSC; HM Treasury; HSE; IPA; and NAO - as well as parliamentary pass-holders from the House of Commons.

This conference focused on the future of local integrated care systems and progress so far on their implementation.

Delegates discussed priorities for developing strategy and effective governance for integrated care following the publication of the NHS England operating framework for ICS structures.

It was an opportunity for stakeholders and policymakers to examine actions laid out in the Hewitt Review, aimed at supporting ICSs to develop and improve care delivery, including the future for:

• balancing freedom with accountability
• providing the space and time for local leadership
• enabling access to transparent, timely and high-quality data

Delegates also discussed the key principles for effective partnership and collaboration across the NHS, primary care, social care and local authorities, looking at progress so far and the key areas where this can be improved.

Further sessions examined the delivery of clinical strategies and the future for coordination of care in managing long-term conditions, as the Major Conditions Strategy is in development.

Attendees also assessed how integrated care can address current challenges in clinical care such as management of care backlogs, waiting times and addressing health inequalities.

We are pleased to have been able to include keynote sessions with Frances Gallagher, Senior Manager, Deloitte; Patricia Hewitt, Chair, The Hewitt Review; Chair, NHS Norfolk and Waveney; and Deputy Chair, Norfolk and Waveney Integrated Care Partnership (pre-recorded presentation); Patricia Miller, Chief Executive Officer, NHS Dorset Integrated Care Board; and Sarah Walter, Director, ICS Network, NHS Confederation.

Overall, areas for discussion included:

• system governance:
  
  • ensuring that best practice governance and leadership cultures are fostered and maintained - providing local leaders with space to lead
  • priorities for engaging local authorities and citizens in structural reform - accountability arrangements
• clinical challenges:
  
  • the way forward for improving clinical care and patient outcomes through integrated care
  • addressing current clinical challenges including waiting times, care backlogs, and health inequalities
• delivering integrated care: joined-up provision - meeting the needs of local areas - delivery of high quality and safe care - next steps for efficient coordination of care
• collaboration: strategies and best practice for building relationships in ICSs - opportunities for supporting primary, social and community care, as well as the voluntary sector
• commissioning: priorities for meeting national targets - developing commissioning structures that prioritise integrated care
• innovation:
  
  • opportunities and challenges for digital transformation, and use of data in supporting operability and collaboration in ICSs
  • providing ICSs with access to data, and equipping them to harness it for improvement, innovation and accountability

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DHSC; DLUHC; DWP; HMPPS; and The Scottish Government.

This conference focused on social prescribing in England, assessing progress and discussing next steps.

It was an opportunity to examine the impact and cost-effectiveness of social prescribing so far, ahead of the review of the Additional Roles Reimbursement Scheme in general practice taking place in early 2024.

Delegates discussed the developing role of social prescribing in tackling loneliness and prescribed medicine dependence, supporting people with cost of living pressures and health inequalities, and improving access to green spaces.

It was also an opportunity to discuss priorities for developing social prescribing programmes and how these can reach new groups, including schools, prisons and veterans, following the National Academy for Social Prescribing being awarded funding to continue granting people access to innovative mental health support.

Further sessions examined the next steps for the social prescribing workforce, including challenges around pay, pressure and capacity, as well as issues with training and support for dealing with complex conditions, and the role of link workers and colleagues in addressing wider challenges in primary care.

Overall, areas for discussion included:

• looking forward: next steps and the longer-term outlook for social prescribing - building the workforce to meet demand - developing local community healthcare partnerships
• integrated care: operating in new ICS structures - developing prevention initiatives - the role of social prescribing in addressing pressures in primary care
• workforce: priorities and challenges for expansion - opportunities for funding and training - engaging the voluntary sector in light of increased pressure on the NHS 
• cost-effectiveness: latest research and thinking on the efficacy of social prescribing - assessing progress on cost savings in the NHS, and expectations for the scale and timing of tangible impacts
• widening delivery: next steps for accessing new groups such as schools, prisons and veterans - utilising funding - developing personalised patient care
• health inequalities: opportunities for further outreach initiatives - reaching communities who have the greatest inequalities - best practice in creating trusted relationships

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DCMS; DfE; DHSC; DSIT; DWP; HMPPS; NAO; OHID; POST; The Scottish Government; and the Welsh Government - as well as parliamentary pass-holders from The House of Lords.

This conference focused on the way forward for the safe and effective use of artificial intelligence in healthcare.

It was a timely opportunity to examine the MHRA’s Software and AI as a Medical Device programme and regulatory framework, which was due for implementation in July 2023.

The discussion also came with a range of wider policy developments including the publication of the A pro-innovation approach to AI regulation white paper, as well as the National AI Strategy, and government initiatives on use of data and digital technologies in healthcare.

Key stakeholders and policymakers assessed challenges for healthcare workers using AI technologies, developing workforce confidence in AI, and involving clinicians in the development of new technologies in the context of the publication of Health Education England’s Developing Healthcare Workers’ Confidence in AI report.

Further sessions looked at:

• the next steps for research, development and implementation of AI in health and social care, and how it can address current and future challenges in healthcare
• opportunities for use of AI to address current clinical challenges including efficiency savings, early diagnosis, waiting times and care backlogs, and health inequalities
• prospects for the UK’s potential leadership in the development and regulation of health and care-related AI

We are pleased to have been able to include keynote sessions with Dominic Cushnan, Director of AI, Imaging and Deployment, NHS England; Clíodhna Ní Ghuidhir, Principal Scientific Adviser for AI, National Institute for Health and Care Excellence; Dr Hatim Abdulhussein, Clinical Fellow, AI and Robotics, and Clinical Lead, Health Education England; Dr Paul Campbell, Senior Clinical Assessor, Software, Medicines and Healthcare products Regulatory Agency; and Dr Russ Pearson, AI Policy Specialist, Medicines and Healthcare products Regulatory Agency.

Overall, sessions in the agenda included:

• the health and social care AI landscape: current use and the future potential of AI in health and social care
• safe and effective use: priority areas for improving outcomes for patients and efficiencies - R&D - investment - support and training for staff - patient trust and engagement
• regulation:
  
  • software and AI roadmap implementation - clarity and guidance for industry - cooperation - agility to keep pace with future developments
  • ensuring patient safety - cybersecurity - data protection - accountability and governance
• workforce: priorities for supporting workforce skills and confidence in AI-based technologies - clinician involvement in the development process and building clinician trust
• R&D: priorities for innovation in AI - next steps for optimising its use in healthcare - developing the use of real-world evidence
• policy: the future for harnessing the potential of AI in healthcare - safe delivery - sector growth - opportunities of UK leadership in AI-powered healthcare and regulation

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the CQC; Department for Education, NI; Department for the Economy, NI; Department of Health, ROI; DHSC; DSIT; FCDO; HMRC; HSE; ICO; IPO; MHRA; NAO; OLS; UKHSA; UKSA; The Scottish Government; and the Welsh Government.

This conference discussed next steps for improving palliative and end of life care.

Following changes to the commissioning of palliative care services through the Health and Care Act last year, delegates discussed how integrated care systems have managed this so far, and priorities for effective delivery going forward.

It was an opportunity to discuss the changes to commissioning structures, including challenges for funding, resource allocation, accountability and transparency, as well as options for commissioning changes to provide improved access and increase collaboration.

Delegates looked at overcoming challenges for engaging primary and secondary care alongside the community, in embedding palliative care into service provision, including the workforce and infrastructure required to support this.

Discussion considered the future for provision of high quality, holistic and personalised care for patients, and the priorities for shared decision-making, research and providing 24/7 support.

We are pleased to have been able to include keynote sessions with Dr Catherine Millington-Sanders, National Clinical End of Life Care Champion, Royal College of General Practitioners and Marie Curie; Max Watson, Programme Director, Project ECHO; and Amanda Williams, Deputy Director, Primary and Community Care, Care Quality Commission.

Overall, areas for discussion included:

• commissioning: next steps and opportunities for the change to commissioning of palliative care in ICBs - addressing increased demand - facilitating access to high quality care
• embedding services: priorities for embedding palliative care in primary, secondary and hospital services - delivering integrated care - funding - infrastructure requirements - improving patient outcomes
• engagement: priorities for engaging primary care and integrating community care - improving collaborative working
• workforce: programmes for recruitment and professional development - retraining staff into palliative care - addressing stakeholder concerns with seven-day working
• personalised care: improving patient outcomes and quality of life after treatment - specialist services, psychological support and personalisation - support for shared family decision-making - 24/7 helplines
• research: key areas for development of research - supporting adoption of innovation - reducing hospital and A&E visits - opportunities for digital health - embedding lessons from the pandemic
• policy: next steps and long-term priorities for end of life and palliative care policy - priorities for regulation and delivery of high-quality, safe palliative and end of life care

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the Cabinet Office; DHSC; DWP; HMPPS; Wales Audit Office; and the Welsh Government.

This conference looked at next steps for using data to deliver and improve health and social care services.

It was an opportunity for stakeholders to examine ambitions laid out in the Government’s Data Saves Lives policy paper, as well as priorities going forward, including in the development of Secure Data Environments (SDEs).

Key stakeholders and policymakers discussed what measures are needed to improve and transform existing health strategies, and build public trust in order to encourage patient engagement.

They considered key issues for supporting safe and effective data use within the health workforce, with a case study session focusing on the transformative use of data to shape patient and care outcomes.

We also expected discussion on how health providers can overcome challenges in utilising data to improve services, the implementation of data protection policies, and the development of digital infrastructure to support integration of data-led processes.

Sessions in the agenda included:

• patient records:
  
  • supporting integration of records across health and social care services - data accuracy, applications and ease of access - building competence in use of and transfer between service providers
• data protection:
  
  • ensuring adherence to digital safety and confidentiality policy across all data-led processes - the role of the Caldicott Guardian - developing data policies - managing records
• public trust in data use:
  
  • enabling equal access to personal health records on request - engaging with patients and relatives on data collection - embedding patient confidentiality into data-led projects
• workforce development:
  
  • developing training programmes to build confidence in data use - patient and treatment management systems - education in data protection policy
  • ensuring accessibility in data-led programmes - priorities for transferring data and records between different digital platforms and systems
• service improvement:
  
  • opportunities for digital transformation in health and social care - enabling cross-service application of data to improve services - patient data hygiene, accuracy and safe use
• policy priorities:
  
  • key issues for implementing government and health provider strategies

We are pleased to have been able to include keynote sessions with James Freed, Chief Digital and Information Officer, Health Education England; Nicole Mather, Life Sciences Lead, IBM; Richard Parker, Legal Director, Hill Dickinson; and Adam Wright, Programme Development Manager, NHS Providers.

The conference was an opportunity for the stakeholders to consider the issues alongside key policy officials who attended from the CMA; DBT; DCMS; Department for the Economy, NI; DESNZ; DHSC; Department of Health, Ireland; HMPPS; Home Office; ICO; MHRA; NAO; OLS; ONS; UK Statistics Authority; The Scottish Government; and the Welsh Government - as well as parliamentary pass-holders from The House of Lords.

This conference discussed priorities for dementia policy in England.

With dementia to be included as part of the new Major Conditions Strategy, instead of the previously expected ten-year strategy for dementia, delegates assessed the long-term strategic priorities for improving health outcomes for dementia, developing integrated holistic care, enabling earlier diagnosis, and the role of social care.

It was also an opportunity to discuss innovative approaches to support services and care in the community, addressing diagnosis backlogs and managing dementia in hospitals and primary care.

Key stakeholders and policymakers examined the next steps for delivering the Dementia Mission as part of the Life Sciences Vision, including opportunities for research and development, investment, collaboration and taking forward treatments in the NHS.

We are pleased to have been able to include keynote sessions with Dr Megan Eldred, Senior Policy Advisor, Dementia Mission Lead, Office for Life Sciences; and Samantha Benham-Hermetz, Director of Policy and Public Affairs, Alzheimer’s Research UK.

Sessions in the agenda included discussion on:

• policy: delivering long-term improvements to dementia diagnosis and care in England
• strategic priorities: moving forward prevention and earlier diagnosis - managing multiple long-term conditions - integrated care and the role of social care - tackling variation and inequalities
• dementia care: addressing diagnosis backlogs - developing effective personalised care - innovative community care and support approaches - managing dementia care within hospitals
• research and treatments: key priorities - R&D investment and collaboration - regulation - equipping the workforce and supporting adoption in the NHS
• Dame Barbara Windsor Dementia Mission: progress and next steps

The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the CQC; DHSC; DSIT; HMPPS; Home Office; MHRA; NAO; and the OHID.